<DOC>
	<DOCNO>NCT02790840</DOCNO>
	<brief_summary>The purpose study compare multiple dose pharmacokinetics ( PK ) three AF-219 formulation ; assess effect Omeprazole multiple dose PK three AF-219 formulation ; , ass safety tolerability AF-219 .</brief_summary>
	<brief_title>A Multiple-Dose Pharmacokinetics Study Three AF-219 Formulations</brief_title>
	<detailed_description />
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Be inform nature study provide write informed voluntary consent Be able speak , read , understand English ; Be healthy male female , race , 18 55 year age , inclusive ; Have body mass index ( BMI ) &gt; 18.5 &lt; 32.0 kg/m2 weigh 50 100 kg ; Be good general health clinically relevant abnormality base medical history , physical examination , clinical laboratory evaluation ( hematology , clinical chemistry , urinalysis ) , 12lead electrocardiogram ; Be nonsmoker intermittent ( social ) smoker least 5 year , able refrain smoking ( use nicotine ) confinement ; If female childbearing potential postmenopausal , agree use 2 form acceptable birth control ; Be able communicate effectively Investigator study center personnel agree comply study procedure restriction Have previously receive AF219 ; Any disease condition might affect drug absorption , metabolism , excretion clinically significant cardiovascular , hematological , renal , hepatic , pulmonary , endocrine , gastrointestinal , immunological , dermatological , neurological , psychiatric disease ; Clinically significant illness clinically significant surgery within 4 week administration study medication ; Any past sinus surgery , upper respiratory tract infection within 2 week dose , history hayfever time year dose take place ; History GERD , heartburn , nausea month , similar symptom require regular use antacid , use H2histamine blocker proton pump inhibitor within 12 month Screening ; QTcB &gt; 450 msec male &gt; 470 msec female ; Known suspect hypersensitivity allergic reaction component AF219 omeprazole capsule ; If female , pregnant breast feeding , positive pregnancy test predose ; Blood loss blood donation &gt; 550 mL within 90 day plasma donation &gt; 500 mL within 14 day administration first dose study drug ; Chronic use systemic medication ( allowable oral implant contraceptive exception vitamins take standard supplement dos ) ; use drug therapy ( include herbal preparation , e.g. , St. John 's wort ) know induce inhibit hepatic drug metabolism within 30 day first dose study medication ; use medication [ prescription overthecounter ( OTC ) ] , include antacid , highdose multivitamin , nutritional supplement , herbal preparation , within 14 day first dose study drug , unless deem acceptable Investigator Sponsor ; Past current history evidence drug alcohol abuse , regular use 2 unit alcohol per day ( 1 unit alcohol = 150 mL wine , 360 mL beer , 45 mL alcohol 40 % ) , use recreational soft drug ( e.g. , marijuana ) within 3 month screen , use hard drug ( cocaine , phencyclidine ( PCP ) , crack ) within 1 year screening , and/or positive screen substance abuse alcohol screen predose ; Ingestion grapefruit grapefruit juice within 48 hour dose administration ; Positive screen hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody ; Receipt investigational product device , participation drug research study within period 30 day ( 5 half life drug , whichever long ) first dose study medication ; Receipt investigational immunomodulator monoclonal antibody within 180 day ( 5 half life , whichever long ) first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Volunteers</keyword>
</DOC>